Liver Cirrhosis: Causes, Complications and Treatment

Liver Cirrhosis: Causes, Complications and Treatment

Liver cirrhosis is an advanced stage of chronic liver injury, in which progressive fibrosis (scarring) replaces functional liver tissue. As fibrous scar tissue accumulates, normal liver architecture — including the vascular channels and hepatocytes that perform the liver's hundreds of metabolic functions — is distorted and destroyed. Cirrhosis can lead to portal hypertension (elevated pressure in the portal venous system) and may eventually lead to liver failure. Treating the underlying cause and complications may help prevent worsening; progression to liver failure is not inevitable.

Cirrhosis affects an estimated 100–120 million people worldwide and causes approximately 1.3 million deaths annually. In China, cirrhosis is particularly prevalent due to the extremely high burden of chronic hepatitis B virus (HBV) infection — China accounts for approximately one-third of all chronic HBV carriers globally.

How Cirrhosis Develops

Chronic liver injury from any cause — if sustained over years — triggers the same fibrotic repair response:

1. Repeated hepatocyte death (from virus, alcohol, fat, or immune attack) triggers inflammation
2. Activated hepatic stellate cells (the liver's "scar cells") proliferate and deposit collagen fibres
3. Fibrous tissue accumulates in the liver parenchyma (perisinusoidal fibrosis) and portal tracts
4. Normal hepatic lobular architecture is replaced by fibrous septa encircling regenerative nodules
5. The vascular architecture is distorted — blood flow through the hepatic sinusoids is obstructed, and portal venous pressure rises (portal hypertension)

Fibrosis progresses from mild (Metavir F1) through significant (F2), advanced (F3 — "pre-cirrhosis"), to established cirrhosis (F4). Fibrosis and some structural and functional changes of cirrhosis may partially regress after effective treatment of the underlying cause (e.g., viral cure or sustained alcohol cessation). Improvement is not assured; portal hypertension and complication risks can persist, so specialist follow-up remains necessary.

Causes

Chronic Hepatitis B (HBV) — Leading Cause in China and Asia

Chronic infection with HBV causes ongoing hepatocyte destruction by immune-mediated attack. HBV cirrhosis develops in approximately 20–40% of chronically infected individuals over 20–40 years. The risk is higher with high viral loads, HBeAg-positive status, alcohol co-use, co-infection with HDV, and male sex.

China has approximately 70–90 million chronic HBV carriers (HBsAg-positive). Long-term antiviral therapy (tenofovir, entecavir) suppresses viral replication and can slow liver-disease progression and reduce hepatocellular carcinoma (HCC) risk. It does not guarantee that fibrosis will stop or reverse in every patient; ongoing specialist monitoring remains necessary.

Chronic Hepatitis C (HCV)

HCV causes insidious liver inflammation over decades — 80% of acute HCV infections become chronic. Approximately 20–30% of chronically infected patients develop cirrhosis within 20–30 years. HCV is now curable with direct-acting antiviral (DAA) agents (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) — 8–12-week oral courses achieve sustained virological response (SVR, effectively cure) in >95% of patients. Achieving SVR usually improves liver injury and may allow fibrosis regression, and reduces — though does not eliminate — HCC risk. Fibrosis can still progress when other liver injury persists, including harmful alcohol use or metabolic liver disease; ongoing follow-up remains important.

Alcohol-Related Liver Disease (ARLD)

Alcohol exposure can cause a spectrum of liver injury, including steatosis, alcohol-associated hepatitis and cirrhosis. The risk of advanced disease depends on the amount and duration of drinking and individual factors; these conditions do not represent an inevitable sequence for every person. Alcohol is the most prevalent cause of cirrhosis in Western countries. Complete abstinence can halt and partially reverse fibrosis; continued drinking in established cirrhosis dramatically worsens prognosis.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

The hepatic manifestation of metabolic syndrome — fat accumulates in hepatocytes (steatosis) in patients with obesity, type 2 diabetes, dyslipidaemia, and hypertension. In approximately 20–25% of those with NAFLD, inflammatory changes (non-alcoholic steatohepatitis — NASH) develop, which can progress to cirrhosis over 15–20 years. NAFLD is now the most rapidly growing cause of cirrhosis and HCC in developed countries.

Other Causes

• Primary biliary cholangitis (PBC) — autoimmune injury to small bile ducts; primary sclerosing cholangitis (PSC) — a separate bile-duct disease whose cause is not established.
• Autoimmune hepatitis (AIH) — autoimmune attack on hepatocytes; responds to immunosuppression
• Hereditary haemochromatosis — iron overload; treated by venesection
• Wilson's disease — copper accumulation; treated with chelation
• Alpha-1 antitrypsin deficiency
• Budd-Chiari syndrome — hepatic vein thrombosis

Stages of Cirrhosis

Cirrhosis is broadly divided into compensated and decompensated:

Compensated cirrhosis — the liver, despite significant fibrosis, maintains adequate function. Patients may be asymptomatic or have only non-specific fatigue, mild right upper quadrant discomfort, and spider naevi on examination. Median survival >12 years. The goal of treatment is to prevent progression to decompensation.

Decompensated cirrhosis — failure of hepatic compensation, defined by the development of one or more of:

• Variceal haemorrhage
• Ascites
• Spontaneous bacterial peritonitis (SBP)
• Hepatic encephalopathy (HE)
• Hepatorenal syndrome (HRS)

Median survival after first decompensation: 1–2 years without liver transplantation.

Complications of Portal Hypertension

Portal hypertension is an increased pressure gradient across the portal circulation. The hepatic venous pressure gradient (HVPG) is a measure used to assess it, not an absolute portal-vein pressure. In viral- and alcohol-related cirrhosis, clinically significant portal hypertension is defined as HVPG ≥10 mmHg. Portal hypertension drives most major complications:

Oesophageal and Gastric Varices

Collateral venous channels develop between the portal and systemic venous systems to decompress the portal pressure. The most dangerous site is the oesophagus and gastric cardia — submucosal varices here may rupture, causing massive, potentially fatal upper GI haemorrhage.

Variceal haemorrhage:

• Presents with haematemesis (vomiting blood) and/or melaena (black tarry stool)
• 6-week mortality approximately 15–20% with modern management; historically 30–50%
• Emergency treatment: IV terlipressin or somatostatin analogue (octreotide); urgent upper GI endoscopy for variceal band ligation (EVL); IV antibiotics (prevent SBP); possibly TIPS (transjugular intrahepatic portosystemic shunt) for refractory bleeding
• Primary prophylaxis: non-selective beta-blocker (propranolol or carvedilol) for large varices before first bleed; or EVL
• Secondary prophylaxis: EVL + beta-blocker after each bleeding episode; TIPS if refractory

Ascites

Accumulation of fluid in the peritoneal cavity — the most common decompensating event (develops in 50% of patients with compensated cirrhosis within 10 years). Caused by sodium and water retention (aldosterone activation), splanchnic vasodilation, and hypoalbuminaemia (low albumin = reduced oncotic pressure).

Treatment:

• Sodium restriction (<88 mmol/day) and aldosterone antagonist diuretics (spironolactone ± furosemide)
• Large-volume paracentesis (LVP) for tense or refractory ascites — drainage volume is individualised, with IV albumin when indicated by the volume removed and the patient's clinical condition to reduce post-paracentesis circulatory dysfunction
• TIPS for refractory ascites unresponsive to diuretics

Spontaneous Bacterial Peritonitis (SBP)

Bacterial infection of ascitic fluid without an obvious surgical cause — translocation of gut bacteria across the impaired gut barrier. Presents with fever, abdominal pain, and deteriorating liver function. Diagnosed by ascitic fluid neutrophil count ≥250/mm³. Treated with IV cefotaxime or ceftriaxone; prophylactic antibiotics (norfloxacin) reduce recurrence. SBP carries approximately 30% in-hospital mortality.

Hepatic Encephalopathy (HE)

Brain dysfunction caused by the liver's failure to detoxify ammonia and other metabolites produced in the gut. The spectrum ranges from subtle cognitive changes (covert HE — including minimal HE and mild grade-one changes, assessed through clinical evaluation and appropriate validated psychometric or neurophysiological tests) to frank confusion, disorientation, personality change, flapping tremor (asterixis), and coma.

Grades (West Haven Criteria):

• Grade 1: Mild confusion, altered sleep
• Grade 2: Moderate confusion, disorientation
• Grade 3: Severe confusion, somnolence
• Grade 4: Coma

Treatment: lactulose (reduces ammonia absorption); rifaximin (antibiotic reducing ammonia-producing gut bacteria); identify and treat precipitants (infection, GI bleeding, dehydration, constipation, sedatives); A history of HE requires careful assessment rather than automatic exclusion from TIPS. Elective TIPS is not recommended with severe or treatment-refractory overt HE when there is no spontaneous shunt that specialists can treat.

Hepatorenal Syndrome (HRS)

Hepatorenal syndrome (HRS) is kidney dysfunction associated with advanced cirrhosis and ascites. Current terminology uses HRS-AKI, HRS-AKD and HRS-CKD according to the timing and duration of kidney dysfunction, rather than the historical type 1/type 2 categories. HRS-AKI assessment considers changes in creatinine and/or urine output, response to volume resuscitation when clinically indicated, and alternative causes of kidney injury; HRS can coexist with structural kidney injury. HRS-AKI needs urgent specialist management, which may include terlipressin with IV albumin and transplantation assessment when appropriate.

Diagnosis and Monitoring

Laboratory Tests

• Liver function tests: elevated bilirubin, low albumin, prolonged INR (prothrombin time) in advanced disease
• Liver blood panel: ALT, AST (often paradoxically normal or low in burned-out cirrhosis), ALP, GGT
• FBC: thrombocytopenia (splenomegaly trapping platelets) is a reliable early sign of portal hypertension
• Aetiology screen: HBsAg, HBV DNA, anti-HCV, HCV RNA, ANA, AMA, ferritin, copper, caeruloplasmin

Non-Invasive Fibrosis Assessment

• Fibroscan (transient elastography): measures liver stiffness in kilopascals and helps assess advanced liver disease. Interpretation depends on the underlying cause, clinical findings and other tests; one stiffness threshold does not by itself establish cirrhosis. False-positive results can occur, so repeat or complementary assessment may be needed. It can reduce the need for liver biopsy in selected settings.
• Blood-based scores: APRI and FIB-4 can be calculated using routine laboratory results and relevant clinical information; ELF requires a separate panel of specialised serum biomarkers.

Liver Biopsy

The historical gold standard — percutaneous needle biopsy provides histological staging. Now reserved for cases where non-invasive tests are inconclusive or where histology changes management (e.g., autoimmune hepatitis grading).

Upper GI Endoscopy

A clinician determines the need for oesophageal-variceal screening using the stage of cirrhosis, non-invasive risk assessment and preventive treatment. Some patients with compensated cirrhosis can avoid screening endoscopy, including those already receiving an appropriate non-selective beta blocker to prevent decompensation. When endoscopy is indicated, repeat timing depends on disease activity, variceal findings and treatment; there is no single interval for everyone.

HCC Surveillance

HCC surveillance should be considered for patients with cirrhosis who could benefit from cancer-directed treatment or liver transplantation. It is not recommended for Child-Pugh C cirrhosis without transplant eligibility, or for life-limiting comorbidities that cannot be addressed by transplantation or other directed treatment. When surveillance is indicated, AASLD recommends ultrasound with AFP approximately every 6 months. MRI is not routinely preferred solely because of HBV or HCV; alternative imaging may be considered when ultrasound surveillance is inadequate.

Treatment

Treating the Underlying Cause

• HBV: tenofovir alafenamide (TAF) or entecavir — selection depends on compensated versus decompensated liver disease and the locally approved product label. TAF must not be assumed suitable in decompensated cirrhosis; a liver specialist should select the regimen. Long-term or lifelong antiviral therapy reduces fibrosis progression and HCC risk.
• HCV: direct-acting antiviral (DAA) treatment aims for sustained virologic response (SVR). Regimen selection and duration require specialist assessment of liver function and other patient factors. Glecaprevir/pibrentasvir is not recommended in decompensated cirrhosis; sofosbuvir/velpatasvir-based options require their own eligibility and treatment assessment.
• Alcohol: complete abstinence — the most important intervention in ARLD; even in established cirrhosis, abstinence substantially improves prognosis
• NAFLD: weight loss (5–10% body weight), metabolic risk factor control; new approved treatment: resmetirom (Rezdiffra) for non-cirrhotic NASH with significant fibrosis
• Autoimmune hepatitis: prednisolone + azathioprine

Liver Transplantation

Liver transplantation is the only definitive treatment for end-stage cirrhosis. It restores normal liver function and cures portal hypertension.

Indications: MELD score ≥15 (Model for End-stage Liver Disease — a score based on bilirubin, INR, and creatinine predicting 3-month mortality); recurrent or refractory decompensation (variceal bleeding, ascites, HE); HCC within Milan criteria (single tumour ≤5 cm or ≤3 tumours all ≤3 cm, with no macrovascular invasion or extrahepatic spread).

Deceased donor transplantation: waiting list allocation based on MELD score.

Living donor liver transplantation (LDLT): a healthy donor (typically a family member) donates their right lobe (60% of total liver volume); the donor's remaining liver can regrow in volume, but this should not be equated with complete recovery of liver function or overall postoperative recovery. Recovery varies between donors and requires individual follow-up with the transplant team. LDLT is particularly developed in Asia, where deceased donor availability is limited by cultural attitudes to organ donation. China's LDLT programme is among the largest in the world.

Liver and GI Care in China

China's hepatology and liver transplantation centres offer:

• Comprehensive hepatitis assessment: HBV/HCV viral load, HBsAg quantification, genotyping, Fibroscan elastography, liver MRI, and haematology
• Hepatitis C treatment: a liver specialist should assess suitable direct-acting antiviral options and treatment duration in the context of liver function and prior treatment. Confirm the specific medicine, availability and price with the treating hospital; this guide does not guarantee access to every regimen or a fixed time to cure.
• HBV long-term treatment: TAF and entecavir available; comprehensive monitoring programme
• TIPS procedure: experienced interventional radiology teams for transjugular intrahepatic portosystemic shunting
• High-volume LDLT programme: among the world's most experienced LDLT centres; comprehensive donor and recipient evaluation
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from assessment through treatment and long-term surveillance

Contact a PriumCare care navigator to arrange a liver disease assessment, hepatitis treatment, or transplantation consultation.

---

Medical content based on MSD Manuals and international hepatology guidelines (EASL, AASLD). Evidence reviewed 2025.

Targeted hepatitis C treatment clarification

Editorial source check: 26 October 2026. This checks only the treatment-access and duration statement above, not the whole article or a medical review. The original publication date is retained.

• WHO: hepatitis C treatment and access

Targeted cirrhosis-management clarification

Editorial source check: 26 October 2026. This update checks only the portal-pressure measurement, TIPS and encephalopathy distinction, HRS classification, HCC surveillance selection, and HCV regimen qualification. It is not a whole-article medical review, adds no named clinical reviewer, and retains the original publication date.

• Baveno VII consensus
• EASL 2025 TIPS guideline
• ADQI–ICA 2024 joint consensus
• AASLD 2023 HCC practice guidance
• AASLD–IDSA HCV Guidance

Targeted cirrhosis course, screening and transplant clarification

Editorial source check: 26 October 2026. This update addresses only the possibility of partial improvement, selection for variceal screening and the stated Milan criteria. It is not a whole-article medical review and adds no named clinical reviewer. The original publication date is retained.

• Baveno VII: portal hypertension consensus
• AASLD: outpatient management of cirrhosis
• AASLD: hepatocellular carcinoma practice guidance

Targeted antiviral eligibility, post-SVR course and stiffness interpretation clarification

Editorial source check: 26 October 2026. This update checks only HBV antiviral selection by hepatic status and applicable product label, residual fibrosis progression after HCV cure, and interpretation of liver stiffness described above. It is not a whole-article medical review, adds no named clinical reviewer, and retains the original publication date.

• AASLD/IDSA HCV Guidance: follow-up after sustained virologic response
• BavenoVII: non-invasive assessment and liver-stiffness interpretation
• FDA: Vemlidy US prescribing information
• EMA: Vemlidy product information

Targeted hepatitis B and alcohol-risk wording clarification

Editorial source check: 26 October 2026. This update checks only the limits of hepatitis B antiviral benefit and the alcohol-associated liver-disease risk description. It is not a whole-article medical review, adds no named clinical reviewer, and retains the original publication date.

• WHO: hepatitis B treatment benefits
• ACG: alcohol-associated liver disease guideline

Targeted editorial source check — 26 October 2026: only the living-donor liver regrowth and recovery statement was reassessed using NHS donor information, NHS Blood and Transplant recovery guidance and NIDDK donor recovery information. Liver-volume regrowth is not a fixed deadline for functional or overall postoperative recovery. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

Targeted editorial source check — 26 October 2026: only the covert hepatic encephalopathy assessment phrase was reassessed against the AASLD/EASL guideline, recommendation 7 and rationale. Clinical assessment and appropriately validated testing are not limited to a single test modality. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

---

Targeted editorial source check — 26 October 2026: The two passages on ELF test inputs and paracentesis volume/albumin scope were checked against the original ELF assay instructions and BSG/BASL ascites guideline. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

---

Targeted editorial source check — 26 October 2026: Only the distinction between PBC-associated autoimmune bile-duct injury and the uncertain cause of PSC was checked against NIH/NIDDK PBC information and NIH/NIDDK PSC information. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

---

Targeted editorial source check — 26 October 2026: The summary and introduction distinguish cirrhosis from eventual liver failure, checked against NIH/NIDDK information. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.